Iberogast Neo (Bitter Candytuft Fresh Plant Extract, Matricaria Liquid Extract, Menthae Piperitae Folium, Melissae)

The botanical extracts in Iberogast Neo act on several physiological pathways: they modulate smooth‑muscle tone, enhance gastric emptying, reduce visceral hypersensitivity, and provide mild anti‑inflammatory and antispasmodic actions through calcium‑channel regulation, nitric‑oxide release and serotonergic receptor interaction.

The dosage of Iberogast Neo is determined by the prescribing healthcare professional based on the patient’s age, condition severity and overall treatment plan. Patients should follow the prescriber’s instructions and the product label.

Safety data for Iberogast Neo in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To request Iberogast Neo, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike single‑active‑ingredient drugs, Iberogast Neo combines several plant extracts, offering a broad‑spectrum approach that targets motility, sensitivity and inflammation simultaneously. It may be preferred by patients seeking a natural, multi‑target option, whereas conventional agents often focus on a single mechanism such as acid suppression or antispasmodic action.

Iberogast Neo should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability and potency.

Iberogast Neo is taken orally, usually as a measured dose of the liquid formulation. The exact volume and frequency are prescribed by a healthcare professional and should be administered according to the label instructions.

Serious risks, although rare, include allergic reactions such as rash, angioedema, severe skin eruptions, liver enzyme elevations and anaphylaxis. Patients should seek immediate medical attention if they experience signs of a severe hypersensitivity reaction.

Iberogast Neo should be avoided in individuals with known hypersensitivity to any of its botanical components, in patients with severe liver disease without medical supervision, and in children under 12 years unless specifically recommended by a qualified clinician.